Meningitis B: Symptoms, Vaccines, and Recent Outbreaks

Meningitis B remains a health concern due to its rapid progression and potential severity, prompting ongoing efforts in prevention and response. Recent cases among students in the UK have highlighted the importance of vaccination and awareness.

The infection is caused by Neisseria meningitidis group B bacteria, which inflame the protective membranes around the brain and spinal cord. If not treated promptly, the condition can become life-threatening within a single day.

Symptoms of meningitis B typically appear within a week of exposure. Common signs include a sudden high fever, a stiff neck, severe headache, confusion, collapse, a red or purple rash, nausea, vomiting, and incoherent speech.

What the numbers show

• At least 29 meningitis B cases were reported in Kent, England since 12 March 2026
• Two deaths have been linked to the 2026 Kent outbreak
• Penbraya was approved by the FDA in October 2023 for ages 10 to 25
• Penmenvy received approval in the United States in February 2025 for the same age group

Vaccination is the primary method for preventing meningitis B. Monovalent vaccines like Bexsero and Trumenba are licensed for protection against serogroup B, while newer pentavalent vaccines such as Penbraya and Penmenvy cover additional serogroups.

Penbraya, which protects against serogroups A, B, C, W, and Y, became available in the United States for individuals aged 10 to 25 following FDA approval in 2023. Penmenvy, another pentavalent vaccine, was approved in 2025 for the same age range.

In March 2026, an outbreak linked to Neisseria meningitidis serogroup B was identified among college and university students in the UK. The outbreak in Kent, England, was associated with a nightclub in Canterbury and resulted in expanded vaccination and chemoprophylaxis measures by the UK Health Security Agency.

Research into improved vaccines continues. The University of Oxford, together with the Serum Institute of India, is developing a quadrivalent MenB vaccine that is expected to provide broader protection and improved safety.

Despite the availability of vaccines, awareness of meningitis B and its prevention remains low among parents of older adolescents and young adults in the United States. Barriers to vaccination include limited provider recommendations, concerns about side effects, and uncertainty about the necessity of the vaccine.

* This article is based on publicly available information at the time of writing.